CAAA601A62301: NETTER-3

The purpose of the current study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 <10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden.

ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT06784752?viewType=Card&id=CAAA601A62301&rank=1

Location: Hartford Hospital

Contact: Hayley Dunnack Yackel: hayley.dunnack@hhchealth.org